PEB-Pacific Edge

[winner (n)]

That's a gloomy report from Craig's eh share guy ....at least they didnt say SELL but then I doubt many of their clients have PEB

And that Stuff story linked used the term 'inflection point' but just any old inflection point as Jackie said it was a  'great inflection point' ......and saying that is often the kiss of death for many stocks

PEB share price should go up next week now.

[Shareguy]

Yes it is.  I think they are generous at $.66.  Lack lustre growth talked up.

[Basil]

LOT of talk over the last two decades and a LOT of "this capital raise will see us through to being cash flow positive"  Frankly I have lost count of how many times I have heard it.

If my own personal experience is anything to go by you will find that Oncologists tell you that you can't beat doing a Cystoscopy https://www.webmd.com/prostate-cancer/guide/cystoscopy, sticking a camera on a tube up your manhood and having a really good look around.  I can tell you from personal experience its not a pleasant experience and you leave your dignity at the door especially when they do a prostate examination for good measure as well.

Frankly I'd rather humiliate myself and be sure than take chances on a test that isn't 100% accurate and that's exactly how the Oncologist explained it to me.

Each to their own but for me they have talked far too much over the years and delivered far to little.  I believe this market is in a state that basically says "show me the money" promises of growth don't cut the mustard any more.

For what its worth having turned 60 last year I no longer care about promises of possible great returns at some distant point...if something isn't eps positive and paying me at least 5%, preferably at least 7% gross, I'm not interested.

[LoungeLizard]

LOT of talk over the last two decades and a LOT of "this capital raise will see us through to being cash flow positive"  Frankly I have lost count of how many times I have heard it.

If my own personal experience is anything to go by you will find that Oncologists tell you that you can't beat doing a Cystoscopy https://www.webmd.com/prostate-cancer/guide/cystoscopy, sticking a camera on a tube up your manhood and having a really good look around.  I can tell you from personal experience its not a pleasant experience and you leave your dignity at the door especially when they do a prostate examination for good measure as well.

Frankly I'd rather humiliate myself and be sure than take chances on a test that isn't 100% accurate and that's exactly how the Oncologist explained it to me.

Each to their own but for me they have talked far too much over the years and delivered far to little.  I believe this market is in a state that basically says "show me the money" promises of growth don't cut the mustard any more.

For what its worth having turned 60 last year I no longer care about promises of possible great returns at some distant point...if something isn't eps positive and paying me at least 5%, preferably at least 7% gross, I'm not interested.

Fair enough, but CXBladder is an accepted, accurate, non-invasive adjunct to a cystoscopy. It isn't designed to replace the cystoscopy but as an easy screening procedure that can even be done in one's home. If the result indicate a problem, then a follow up cystoscopy is required. It has cleared all the trials, testing and regulatory hurdles and has been endorsed by many of the larger health care providers in the US, including Medicare and MedicAid. The question is, now that the hard work has been done, are we at a cusp of an acceleration in it's use? I'm prepared to be wrong, but I'm getting a good feeling from the increasing numbers and the confidence shown by PEB in starting quarterly reporting off those numbers. Too soon to say "inflection point" (which as you say, is often the kiss of death) but I think the next 12 months will determine whether PEB take off, or ultimately fade away.

[Shareguy]

AGM this week.  Insert from Forbars most recent note.  Forbar have target price of $1.05 "Outperform"

Hopefully after two positive anouncements the AGM will offer further insight.

Limited outlook commentary although momentum appears to be improving
COVID-19 has had a profound impact on PEB's ability to drive revenue growth, with limited urologist access for PEB's sales reps. However, against this backdrop following its CMS coverage decision and Kaiser agreement in mid-2020 PEB has grown revenue at a FY20–FY22 CAGR of +63% (off a low base). Outlook commentary lacked quantitative details, however, as the prevalence of COVID-19 abates recent signs showcase an uptick in throughput with "average weekly test throughput in the US from the start of April to last week, +25% higher than the average of the last year". In addition, we estimate total USA lab throughput in April is up ~+60% versus the end of FY21 on the back of a material increase in volumes through April. Over the near/medium-term we see a number of catalysts that have the potential to drive the share price (including Kaiser Permanente ramp up, new commercial agreements, stronger mention/inclusion in guidelines, and further clinical evidence).

[Left Field]

PEB investing in key people, and adding to their payroll costs.

https://www.directbroking.co.nz/DirectTrade/dynamic/announcement.aspx?id=6081679

Always a fine line for small cap companies, balancing the management of what little cash they have, while seeking to expand their expertise and market clout.

Interesting times.

[Pierre]

PEB investing in key people, and adding to their payroll costs.

https://www.directbroking.co.nz/DirectTrade/dynamic/announcement.aspx?id=6081679

Always a fine line for small cap companies, balancing the management of what little cash they have, while seeking to expand their expertise and market clout.

Interesting times.

I think this appointment shows the new MD is really serious about driving growth for PEB. The company has a significant war chest from the recent cap raise so funding is not an issue - and wont be in the future as the top line continues to improve.

[Pierre]

Peter Meintjes impressed me at the Annual Meeting as confident, intelligent and knowledgeable and to have a clear strategy for growth. It was obvious from his comments there is a great degree of complexity to be navigated in the US market but, in conjunction with the equally impressive David Levinson on the US side, I feel the company is in very good hands and the future is bright.

It was especially pleasing to hear the chairman state that the company believes it has sufficient financial resource to take the company through to cash flow positivity and profitability without requiring an additional capital raise.

[Shareguy]

Thanks Pierre for the update. No more additional capital raises is great news. Yes seems very positive.

[Basil]

Peter Meintjes impressed me at the Annual Meeting as confident, intelligent and knowledgeable and to have a clear strategy for growth. It was obvious from his comments there is a great degree of complexity to be navigated in the US market but, in conjunction with the equally impressive David Levinson on the US side, I feel the company is in very good hands and the future is bright.

It was especially pleasing to hear the chairman state that the company believes it has sufficient financial resource to take the company through to cash flow positivity and profitability without requiring an additional capital raise.

With all due respect we have heard exactly that so many times before I have lost count.

From memory Forbar have been involved in quite a number of those capital raises so who are they really acting for when they come out with a positive outlook ?  Independent research for clients of earning Brownie points towards more investment banking business ?

Until they really are eps positive with a bright outlook I think a VERY high degree of caution is warranted with any forward looking statements this company makes

[Pierre]

With all due respect we have heard exactly that so many times before I have lost count.

From memory Forbar have been involved in quite a number of those capital raises so who are they really acting for when they come out with a positive outlook ?  Independent research for clients of earning Brownie points towards more investment banking business ?

Until they really are eps positive with a bright outlook I think a VERY high degree of caution is warranted with any forward looking statements this company makes

I can't recall ever hearing such a positive comment about cash from the company, but even if they have said it before, this time it is certainly a credible statement when they are holding around $100m from last year's cash raise.

I am well aware you are not a PEB fan, and for many shareholders - me included- it has been a roller coaster ride over the years. Still, in 2-3 years time you might be regretting you didn't buy a ticket.

[Left Field]

You cannot view this attachment.You cannot view this attachment.You cannot view this attachment.

Thanks Pierre, these slides from the FY22  presentation sum up PEB's position v well IMO.

[winner (n)]

REALLY BIG NEWS on the way ..... or maybe takeover (ie get out of jail card) at $1.50

Trading halt can't be for anything bad

[Left Field]

REALLY BIG NEWS on the way ..... or maybe takeover (ie get out of jail card) at $1.50

Trading halt can't be for anything bad

Exciting, roll on Monday's news!

FWIW - I would prefer a partial acquisition/investment in PEB from a major strategic partner to help strengthen the balance sheet and take the company forward. Imagine FPH buying in. Crikey.

ps link to ODT article on yesterday's ASM. https://www.odt.co.nz/business/pacific-edge-focus-building-sustainable-value

[Pierre]

I am well aware you are not a PEB fan, and for many shareholders - me included- it has been a roller coaster ride over the years. Still, in 2-3 years time you might be regretting you didn't buy a ticket.

Depending on what the Trading Halt is about, Basil Beagle may be regretting he didn't buy a ticket for the PEB roller coaster yesterday.